Table 2.
Summary of the 22 primary GI MCL cases.
| Case # | Age/sex | GI presentation | Year of Dx | Initial therapy | Response | Progression | PFS (mo) | Subsequent therapy | Vital status, COD | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 56/M | Multiple polyps in small bowel | 1992 | Unknown | Unknown | Yes | 6.7 | ASCT | D, MDS | 92.5 |
| 2 | 70/M | Multiple polyps in colon and rectum | 1994 | Surgery followed by observation | CR | Yes | 72.9 | Missing | D, Unknown | 224.6 |
| 3 | 68/M | Multiple polyps in colon | 1996 | CHOP | CR | Yes | 25.5 | Cladribine | D, MCL | 49.3 |
| 4 | 78/M | Multiple polyps in colon | 1997 | Radiation therapy followed by observation | CR | Yes | 28.5 | Rituximab | A | 215.2 |
| 5 | 55/M | Multiple polyps in colon | 1997 | CHOP | CR | Yes | 35.3 | Cladribine | A | 101.5 |
| 6 | 77/F | Single polyp in terminal ileum | 2000 | Polypectomy followed by observation | CR | Unknown | 118.0 | Unknown | D, Unknown | 118.0 |
| 7 | 45/M | Multiple polyps in colon | 2001 | CHOP | PR | Unknown | 42.7 | Unknown | D, Unknown | 42.7 |
| 8 | 45/M | Multiple polyps in stomach, small bowel, colon, and appendix | 2001 | R-CHOP followed by ASCT | CR | Yes | 48.7 | Allogeneic stem-cell transplant | A | 194.5 |
| 9 | 55/M | Multiple polyps in stomach, small bowel, and colon | 2002 | R-HyperCVAD | CR | Yes | 37.1 | Rituximab and then gemcitabine | D, MCL | 81.3 |
| 10 | 50/M | Multiple polyps in duodenum, small bowel, and colon | 2002 | R-CHOP | CR | Yes | 32.5 | Cladribine and then bortezomib | D, MCL | 59.9 |
| 11 | 47/M | Areas of mild nodularity in the stomach | 2003 | Helicobacter pylori therapy and observation | CR | Yes | 18.8 | R-CHOP followed by ASCT | A | 80.3 |
| 12 | 69/M | Single polyp in colon | 2003 | Rituximab monotherapy | CR | Yes | 84.3 | Rituximab and then everolimus | D, others | 94.6 |
| 13 | 43/M | A large ulcerated gastric mass with regional lymphadenopathy | 2004 | R-CHOP followed by ibritumomab tiuxetan | CR | Yes | 9.0 | High-dose chemotherapy followed by ASCT | D, MCL | 35.0 |
| 14 | 62/M | A colonic mass and an ileal mass with regional lymphadenopathy | 2006 | R-CHOP | CR | Yes | 81.8 | Cladribine | A | 84.3 |
| 15 | 79/M | Multiple polyps in colon | 2007 | Rituximab monotherapy | CR | Yes | 17.3 | Rituximab monotherapy | A | 141.9 |
| 16 | 49/M | Multiple polyps in colon and small bowel | 2008 | R-maxi CHOP alternating with R-AraC followed by ASCT | CR | No | 33.2 | Not applicable | A | 33.2 |
| 17 | 73/M | Single polyp in colon | 2009 | Polypectomy followed by observation | CR | Yes | 95.5 | Bendamustine and rituximab | A | 102.1 |
| 18 | 73/F | Single gastric lesion | 2009 | Bendamustine and rituximab | CR | No | 27.8 | Not applicable | D, Pancreatic cancer | 27.8 |
| 19 | 79/F | Single polyp in stomach and multiple lesions in terminal ileum, cecum, and colon | 2010 | Bortezomib-containing regimen | Unknown | Yes | 11.2 | Unknown | D, Unknown | 19.3 |
| 20 | 62/M | Multiple polyps in rectum and small bowel | 2011 | R-HyperCVAD | PD | Yes | 3.5 | Bendamustine and rituximab | A | 8.2 |
| 21 | 51/M | Multiple polyps in colon | 2012 | Bendamustine and rituximab followed by ASCT | CR | No | 67.5 | Not applicable | A | 67.5 |
| 22 | 61/M | Patchy areas of erythema and erosion in stomach | 2014 | Observation | SD | Yes | 15.7 | Bendamustine and rituximab followed by rituximab maintenance | D, Unknown | 48.4 |
Abbreviations: GI gastrointestinal, MCL mantle cell lymphoma, M male, F female, Dx diagnosis, CHOP cyclophosphamide, doxorubicin, vincristine, prednisone, R rituximab, R-HyperCVAD rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with rituximab plus high-dose methotrexate and cytarabine, ASCT autologous stem-cell transplant, CR complete response, PR partial response, SD stable disease, PD progressive disease, PFS progression-free survival, OS overall survival, A alive, D deceased, COD cause of death, mo months MDS myelodysplastic syndrome.